Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced today that trading of its ordinary shares on the regulated market of Euronext Paris ("Euronext Paris") will be temporarily halted, at the Company’s request, from the opening of the market at 9:00 a.m. (CET). This trading halt takes place in the context of the previously announced public offering by the Company in the United States only of new American Depositary Shares (the "ADSs"), each representing one new ordinary share of the Company with a nominal value of €0.01 (the "Offering"), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Offering.

This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume today, November 13, 2025, at approximately 3:30 p.m. (CET), which is the earliest time ADSs are expected to begin trading on the Nasdaq Global Market (9:30 am (ET)), under the ticker symbol "IVA".

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com     

Contacts

Inventiva Pascaline Clerc EVP, Strategy and Corporate Affairs [e-mail] [phone]

ICR Healthcare Media Relations Alexis Feinberg  [e-mail] [phone]

ICR Healthcare Investor relations Patricia L. Bank [e-mail] [phone]

Important Notice 

This press release contains certain forward-looking statements with respect to the proposed trading halt. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements.